CAS番号を超えた変更管理の文書化により、 変更リスクを低減。

主要特性 在三个通过ISO 13485认证的医疗生产线生 产全球统一的配方，提供全球一致性和供应 链保障 变更控制记录不限于CAS编号级别，降低变 更风险 不含动物源性物质和邻苯二甲酸盐 可用作各种聚合物的母粒或即用型配方 为方便起见，可在一个产品中实现功能性和颜 色的组合 法规支持 经过预测试的原材料： - ISO 10993-1 - USP 第、章（VI类） - USP （指南），6.2.3 可萃取元素； USP - ICHQ3D/USP 2 可萃取金属 - 欧洲药典 3.1 聚烯烃（如适用） FDA发布的注册药品主文件（III类）和/或医疗 器械主文件 为符合（新）法规（如IVDR）的批准或过渡提 供文档支持 适用医疗保健使用限制—见下文。

Global Compact & fulfilled Communication of Progress (COP) requirements • New Sustainability Strategy overview page including our 2022 AIP ESG metrics • New ESG Performance page with ESG ratings, awards, and certifications • Increased disclosures on carbon emissions, including disclosure of Climate Change Scenario Analysis • Added new Product Stewardship and Chemical Management policies • Enhanced data reporting for Workforce Demographics • Improved social disclosures on human rights, dependent care and special leave and strategic training management 2021 SUSTAINABILITY REPORT Launching integrated sustainability website in parallel with report Aligned with leading reporting frameworks 6 Released July 2022 ESG RATINGS PERFORMANCE ESG AWARDS AND CERTIFICATIONS ESG PERFORMANCE & AWARDS 84th 3 1 2 7 T RAN S FO R MAT IO NAL OVE RV IE W Avient Protective Dyneema ® RECENT TRANSACTIONS Acquired Divested $1.45 B $0.95 B 9 Distribution UPDATED CAPITAL STRUCTURE & LIQUIDITY • Proceeds from completed sale of Distribution used to pay near-term maturing debt to strengthen balance sheet • Fixed/floating debt ratio of ~55/45 • Proven track record of deleveraging following major acquisitions through strong free cash flow generation • 2022 pro forma net debt/adjusted EBITDA expected to be 3.1x $725 $725 $575 $500 $600 $525 $650 $650 $600 Capital Structure Cas h $544 Undr awn Rev olve r $250 Liquidity $3.15B $2.40B 2030 Notes 2029 Term Loan 2026 Term Loan 2025 Notes 2023 Notes After Dyneema Acquisition After Distribution Divestiture $794M (1) $250M reflects estimated undrawn revolver following the divestiture of Distribution 10 PREVIOUS TRANSACTIONS Performance Solutions Products & $0.8 B COLOR $1.4 B Acquired (2020)Divested (2019) 11 • Acquisition of Clariant Color business significantly expanded presence in healthcare, packaging and consumer end markets • Strength of portfolio – double-digit annual EBITDA growth since acquisition • $75 million of realized synergies anticipated in 2022 • Acquisition completed on July 1, 2020 for $1.45 billion.

Except in the case of a force majeure, if not satisfied with Seller’s determination, Buyer as its sole remedy shall have a right to terminate this contract without further obligation upon: (i) 10 days written notice; and (ii) payment for all Product received to date. 12.

Microsoft Word - Compensation Committee Charter (REV 10-2019)3[1].docx AVIENT CORPORATION COMPENSATION COMMITTEE CHARTER Membership • The Committee will consist entirely of directors who meet the definition of “independent” as set forth in the Corporate Governance Standards of the New York Stock Exchange, including the additional independence requirements set forth in New York Stock Exchange Listed Company Manual Section 303A.02(a)(ii)

CAS番号を超えた変更管理を文書化し、変更 リスクを低減。

Except in the case of a force majeure, if not satisfied with Seller’s determination, Buyer as its sole remedy shall have a right to terminate this contract without further obligation upon: (i) 10 days written notice; and (ii) payment for all Product received to date. 12. Excepto en el caso de Fuerza Mayor, si el Comprador no está satisfecho con la determinación del Vendedor, el Comprador como único recurso tendrá derecho a rescindir el presente contrato sin más obligación que: (i) dar aviso por escrito con 10 días de anticipación, y (ii) el pago de todo el Producto recibido hasta la fecha. 12.

You can find ideas applying this circular ecosystem to modern economics and manufacturing as far back as post-World War II.

Meet with management and the independent auditor prior to the audit and discuss (i) their responsibilities under generally accepted auditing standards, (ii) the responsibilities of management in the audit process and (iii) the overall scope and plans for the audit, including the adequacy of staffing and other factors that may affect the effectiveness and timeliness of the audit.

A NR II - 680/91; AKT NOTARIALNY Z 12.02.2002 R, NOTARIUSZ MAŁGORZATA Strona 1 z 8 Z.